Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.49 |
| ▸ | ACVRL1 | P37023 | 16/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279744 | 0.85 | FGFR1 (0.40) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL15020407 | 0.84 | FGFR1 (0.47) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279403 | 0.84 | FGFR1 (0.39) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279610 | 0.84 | FGFR1 (0.39) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279415 | 0.79 | FGFR1 (0.39) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279456 | 0.75 | FGFR1 (0.34) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL10118030 | 0.74 | FGFR1 (0.38) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279736 | 0.73 | FGFR1 (0.46) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279504 | 0.73 | ACVRL1 (0.41) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL10225290 | 0.73 | FGFR1 (0.44) | FGFR1FGFR3ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829185-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120165314-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2012-06-28 | — | — | US | disclosed |
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165314-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, FLT4, CDKL4 | FGFR1 19/4885FGFR3 284/4885ACVRL1 1003/4885 |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | CDK4, FLT4, CDKL4 | FGFR1 19/4885FGFR3 284/4885ACVRL1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.